InsiderTrades

Form 4 for VBIO Valion Bio, Inc.

Accepted 2026-09-24 16:45:35 ET · period of report 2026-09-18 · accession 0001683168-26-007396 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-09-24 16:45 2026-09-18 VBIO Wolf Lisa G COO, CFO M - OptEx — +4 29 +16% —
D 2026-09-24 16:45 2026-09-18 VBIO Wolf Lisa G COO, CFO F - Tax $2.12 -2 27 -7% -$4.24
D 2026-09-24 16:45 2026-09-18 VBIO Wolf Lisa G COO, CFO M - OptEx $0.00 -4 19 -17% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-09-18 M A 4 — 29 D — — (F1) Each Restricted Stock Unit is convertible into one share of Common Stock. (F3) Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.
2 Common Common Stock 2026-09-18 F D 2 $2.12 27 D — — (F2) The Reporting Person forfeited 2 shares of Common Stock upon vesting and settlement of 4 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's Common Stock at the time of forfeiture. (F4) These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.
3 Derivative Restricted Stock Units 2026-09-18 M D 4 $0.00 19 D — · — to — 4 Common Stock (F1) Each Restricted Stock Unit is convertible into one share of Common Stock. (F3) Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. (F3) Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. (F4) These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.